Jonathan Gardner's articles Biotechnology Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound. Written by Jonathan Gardner November 26, 2024November 26, 2024 Saving Bookmark this article Bookmarked Biotechnology Roche turns to a startup in search for new breast cancer drugs The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly. Written by Jonathan Gardner September 30, 2024September 30, 2024 Saving Bookmark this article Bookmarked Biotechnology FDA approves Amgen drug for tough-to-treat type of lung most cancers Imdelltra, a bispecific antibody focusing on a protein known as DLL3, is cleared to be used following chemotherapy in treating extensive-stage small cell lung most cancers. Written by Jonathan Gardner May 20, 2024May 20, 2024 Saving Bookmark this article Bookmarked Biotechnology European regulator concludes no suicide hyperlink to weight problems medication The choice clears a priority hanging over GLP-1 medicines like Ozempic since studies of suicidal ideation and self-harm amongst folks taking the medication surfaced in July. Written by Jonathan Gardner April 15, 2024April 15, 2024 Saving Bookmark this article Bookmarked Biotechnology Gilead expands Arcellx cancer cell therapy deal The deal gives Gilead an estimated 13% ownership in Arcellx and extends the company’s cash runway into 2027. Written by Jonathan Gardner November 15, 2023November 15, 2023 Saving Bookmark this article Bookmarked
Biotechnology Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound. Written by Jonathan Gardner November 26, 2024November 26, 2024 Saving Bookmark this article Bookmarked
Biotechnology Roche turns to a startup in search for new breast cancer drugs The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly. Written by Jonathan Gardner September 30, 2024September 30, 2024 Saving Bookmark this article Bookmarked
Biotechnology FDA approves Amgen drug for tough-to-treat type of lung most cancers Imdelltra, a bispecific antibody focusing on a protein known as DLL3, is cleared to be used following chemotherapy in treating extensive-stage small cell lung most cancers. Written by Jonathan Gardner May 20, 2024May 20, 2024 Saving Bookmark this article Bookmarked
Biotechnology European regulator concludes no suicide hyperlink to weight problems medication The choice clears a priority hanging over GLP-1 medicines like Ozempic since studies of suicidal ideation and self-harm amongst folks taking the medication surfaced in July. Written by Jonathan Gardner April 15, 2024April 15, 2024 Saving Bookmark this article Bookmarked
Biotechnology Gilead expands Arcellx cancer cell therapy deal The deal gives Gilead an estimated 13% ownership in Arcellx and extends the company’s cash runway into 2027. Written by Jonathan Gardner November 15, 2023November 15, 2023 Saving Bookmark this article Bookmarked
